Riskpilot← Back to searchSign inGet full accessInwound ApS
APSActiveCVR 39766612Herlufsholmvej 37, 1.Research and experimental development on natural sciences and engineering · NACE 7210Est. 20186 employeeshttp://www.inwound.com/
Revenue 2024
DKK -2M
+157% vs 2023
EBITDA margin
189.7%
-65% vs 2023
Equity ratio
44.7%
Financial strength
Net profit 2024
DKK -1M
+51% vs 2023
| Revenue | DKK -2M | +157% |
| EBITDA | DKK -3,7M | -65% |
| Net profit | DKK -1M | +51% |
| Total assets | DKK 7,9M | +273% |
| Equity | DKK 3,5M | +166% |
| Employees | 6 | — |
Legal name
Inwound ApS
CVR number
39766612
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
1. august 2018
Share capital
DKK 215.966
Employees
6 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsens formand i forening med en direktør eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at udvikle, kommercialisere, fremstille og sælge et laserapparat til heling af sår.
Address
Herlufsholmvej 37, 1.
Email
lasse@inwound.com
Website
http://www.inwound.com/
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | -921 | -72 | -857 | -988 | -767 | -1.969 |
| Staff expenses | -977 | -678 | -1.423 | -1.503 | -1.490 | -1.766 |
| EBITDA | -1.898 | -751 | -2.280 | -2.492 | -2.257 | -3.734 |
| Depreciation & amort. | -9 | -28 | -17 | -24 | -24 | -24 |
| EBIT | -1.908 | -778 | -2.297 | -2.515 | -2.281 | -3.758 |
| Net financials | -31 | -34 | -382 | -379 | -393 | 2.739 |
| Profit before tax | -1.939 | -812 | -2.679 | -2.895 | -2.674 | -1.020 |
| Tax | -413 | -304 | -528 | -554 | -586 | 6 |
| Net profit | -1.526 | -508 | -2.151 | -2.341 | -2.088 | -1.026 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | 732 | 2.012 | 4.280 | 2.386 | 2.119 | 7.901 |
| Equity | -586 | -1.094 | -2.245 | -4.586 | -5.311 | 3.530 |
| Long-term debt | 1.197 | 2.999 | 6.399 | 6.708 | 7.158 | 4.093 |
| Short-term debt | 120 | 107 | 125 | 263 | 272 | 279 |
| Total debt | 1.317 | 3.106 | 6.524 | 6.972 | 7.430 | 4.372 |
EBITDA margin
-373437500.0%
This company
15.8%
Market median
-2363528581% vs market
20192024
Equity ratio
44.7%
This company
38.2%
Market median
+17% vs market
20192024
Return on equity
-29.1%
This company
18.4%
Market median
-258% vs market
20192024
Net profit margin
-102593200.0%
This company
8.1%
Market median
-1266582816% vs market
20192024
Asset turnover
-0.25×
This company
1.12×
Market median
-122% vs market
20192024
Debt / equity
1.24×
This company
0.62×
Market median
-100% vs market
20192024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2018-08-01 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
LB Chief Executive Officer | Chief Executive Officer | 2026 | — | — |
JB Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
SS Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2018 | — | — | |
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2019 | — | — | |
| Board of Directors | 2025 | — | — | |
| Chairman | 2026 | — | — | |
| Board of Directors | 2025 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Akk Biotek Holding ApS | Company | 50.0% | 50.0% | 2024 |
WINDING ROADS ApS | Company | 10.0% | 10.0% | 2024 |
K Fischer Hansen ApS | Company | 5.0% | 5.0% | 2024 |
InWound Invest ApS | Company | 5.0% | 5.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Akk Biotek Holding ApS
Inwound ApS Board members of Inwound ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lasse Blirup Snejbjerg | Chief Executive Officer | 0 companies |
| Janus Beierholm | Chief Executive Officer | 0 companies |
| Sophia Sara Leth | Chief Executive Officer | 0 companies |
| Claus Ivan Rehfeld | Chairman | 0 companies |
| Søren Georg Jensen | Board of Directors | 0 companies |
| Sven Per Magnus Ågren | Board of Directors | 0 companies |
| Simon Joshua Gabriel | Board of Directors | 0 companies |
| Torsten Dahl Fredelund | Board of Directors | 0 companies |
| Bjørn Broby Glavind | Board of Directors | 0 companies |
| Helge Holm-Larsen | Board of Directors | 0 companies |
| Bent von Eitzen | Board of Directors | 0 companies |
| Carl Morten Bilbo | Chairman | 0 companies |
| Christopher Bromley | Board of Directors | 0 companies |